Meet our SPARK Fellows

Introducing Cohort 7

Jessica Rove, MD

Jessica Rove, MD

Colorado Chest Tube

Juan-Pablo Idrovo, MD

Juan-Pablo Idrovo, MD

Gastrostomy Tube Guardian

Rui Zhao, PhD

Rui Zhao, PhD

Developing a First-in-Class Allosteric Eya2 Tyrosine Phosphatase Inhibitor for Brain Cancer Therapy

Sujatha Venkataraman, PhD

Development of Gated Dual-antigen Targeting CAR-T Cell Therapy to Treat ATRT, an Aggressive Brain Tumor in Children

zhirui_wang_500

Zhirui Wang, PhD

Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia and Other CD47+ Cancers

Cohort 6

Dr. Park

Daewon Park, PhD

Microbicidal Polymer Spray

Microbicidal Polymer Spray

Tegsal is developing an antimicrobial polymer platform technology. They recently completed an NSF I-Corps cohort, which led to significant validation of commercial potential of their technology. Currently, they are investigating the applicability and impact of their technology across multiple clinical areas of interest, including as a multi-modal wound dressing prehospital trauma and combat casualty care. Collaborators: Luke Duncan, MS, MBA, Elizabeth Schiesser, MSc and Barry Marston

Learn more about Dr. Park

Cohort 5

Dr. Park

Daewon Park, PhD

Microbicidal Polymer Spray

Microbicidal Polymer Spray

Tegsal is developing an antimicrobial polymer platform technology. They recently completed an NSF I-Corps cohort, which led to significant validation of commercial potential of their technology. Currently, they are investigating the applicability and impact of their technology across multiple clinical areas of interest, including as a multi-modal wound dressing prehospital trauma and combat casualty care. Collaborators: Luke Duncan, MS, MBA, Elizabeth Schiesser, MSc and Barry Marston

Learn more about Dr. Park

Cohort 4

Dr. Park

Daewon Park, PhD

Microbicidal Polymer Spray

Microbicidal Polymer Spray

Tegsal is developing an antimicrobial polymer platform technology. They recently completed an NSF I-Corps cohort, which led to significant validation of commercial potential of their technology. Currently, they are investigating the applicability and impact of their technology across multiple clinical areas of interest, including as a multi-modal wound dressing prehospital trauma and combat casualty care. Collaborators: Luke Duncan, MS, MBA, Elizabeth Schiesser, MSc and Barry Marston

Learn more about Dr. Park

Cohort 3

Cohort 2

Cohort 1

CU Innovations

CU Anschutz

Anschutz Health Sciences Building

1890 N Revere Ct

Suite 6202

Mail Stop F411

Aurora, CO 80045


303-724-3720

CMS Login